May. 19 at 2:23 PM
Noble Capital Markets Research Report: Eledon Pharmaceuticals (
$ELDN) – 1Q25 Reported With Phase 2 Results Expected In 4Q25
1Q25 Had Lower Expenses Than We Projected. Eledon reported a loss of
$6.5 million or $(0.08) per share, including a gain of
$10.1 million related to fair value of warrant liabilities. Without this one-time item, the loss would have been
$16.6 million or $(0.21) per share, as Research and Development expense increased less from the previous quarters than we anticipated. We expect R&D to be relatively steady as the Phase 1b and Phase 2 BESTOW trials conclude later in FY2025. Cash on March 31, 2025, was
$124.9 million.
Read more: https://www.channelchek.com/news-channel/eledon-pharmaceuticals-eldn-1q25-reported-with-phase-2-results-expected-in-4q25
